

[Influenza \(Flu\) \(/flu/index.htm\)](/flu/index.htm)



[Influenza \(Flu\) \(/flu/index.htm\)](/flu/index.htm)

Weekly U.S. Influenza Surveillance Report

Updated December 1, 2023



A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Key Updates for Week 47, ending November 25, 2023

Seasonal influenza activity continues to increase in most parts of the country, most notably in the South Central, Southeast, Mountain, and West Coast regions.

Viruses

Clinical Lab

6.2% (Trend ↑)
positive for influenza
this week

[\(/flu/weekly/index.htm#ClinicalLaboratories\)](/flu/weekly/index.htm#ClinicalLaboratories)

Public Health Lab

The most frequently reported
influenza viruses this week were
influenza A(H1N1).

[\(/flu/weekly/index.htm#PublicHealthLaboratories\)](/flu/weekly/index.htm#PublicHealthLaboratories)

Virus Characterization

Genetic and antigenic
characterization and antiviral
susceptibility are summarized in
this report.
[\(/flu/weekly/index.htm#VirusCharacterization\)](/flu/weekly/index.htm#VirusCharacterization)

Illness

Outpatient Respiratory Illness

3.9% (Trend ↑)

of visits to a health care provider this week were for respiratory illness
(above baseline).

[\(/flu/weekly/index.htm#ILINet\)](/flu/weekly/index.htm#ILINet)

Outpatient Respiratory Illness: Activity Map

This week 10 jurisdictions experienced moderate activity and 13 jurisdictions experienced high or very high activity.

[\(/flu/weekly/index.htm#ORIAM\)](/flu/weekly/index.htm#ORIAM)

FluSurv-NET

3.7 per 100,000
cumulative hospitalization rate.

[\(/flu/weekly/index.htm#FluSurvNet\)](/flu/weekly/index.htm#FluSurvNet)

NHSN Hospitalizations

4,268 (Trend ↑)
patients admitted to hospitals with influenza this
week.

[\(/flu/weekly/index.htm#NHSN\)](/flu/weekly/index.htm#NHSN)

NCHS Mortality

0.1% (Trend →)
of deaths attributed to influenza this week.

[\(/flu/weekly/index.htm#NCHSMortality\)](/flu/weekly/index.htm#NCHSMortality)

Pediatric Deaths

5
influenza-associated deaths reported this week for a
total of 8 so far this season

[\(/flu/weekly/index.htm#PedMortality\)](/flu/weekly/index.htm#PedMortality)

All data are preliminary and may change as more reports are received.

Directional arrows indicate changes between the current week and the previous week. [Additional information \(/flu/weekly/index.htm#Trends\)](#) on the arrows can be found at the bottom of this page.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the [surveillance methods \(/flu/weekly/overview.htm\)](#) page.

Additional information on the current and previous influenza seasons for each surveillance component are available on [FluView Interactive \(/flu/weekly/fluviewinteractive.htm\)](#).

Key Points

- Seasonal influenza activity continues to increase in most parts of the country, most notably in the South Central, Southeast, Mountain, and West Coast regions.
- Outpatient respiratory illness is above baseline¹ nationally for the fourth week and is at or above baseline in eight of 10 HHS Regions. Region 7 (Central) is at its region-specific outpatient respiratory illness baseline and regions 1, 2, 4, 5, 6, 8, and 9 (New England, New York/New Jersey/Puerto Rico/Virgin Islands, Midwest, Southeast, South Central, Mountain, and West Coast) are above their region-specific baselines.
- The number of weekly flu hospital admissions continues to increase.
- In week 47, 5 pediatric deaths associated with influenza were reported. This brings the 2023-2024 season total to 8 pediatric deaths.
- During week 47, of the 379 viruses reported by public health laboratories, 311 (82.1%) were influenza A and 68 (17.9%) were influenza B. Of the 202 influenza A viruses subtyped during week 47, 166 (82.2%) were influenza A(H1N1) and 32 (17.8%) were A(H3N2).
- CDC estimates that there have been at least 1.8 million illnesses, 17,000 hospitalizations, and 1,100 deaths from flu so far this season.
- CDC recommends that everyone 6 months and older get an annual flu vaccine, as there are still vaccines available.² Now is still a good time to get a vaccine, if you haven't already.
- There also are prescription flu antiviral drugs that can be used to treat flu illness; those should be started as early as possible and are especially important for higher risk patients.³
- Influenza viruses are among several viruses that contribute to respiratory disease activity. CDC is providing updated, integrated information (<https://www.cdc.gov/respiratory-viruses/index.html>) about COVID-19, influenza, and RSV activity on a weekly basis.

U.S. Virologic Surveillance

<https://www.cdc.gov/flu/weekly/overview.htm#LabSurveillance>

Nationally and in HHS Regions 1, 2, 3, 4, 8, 9, and 10, the percentage of respiratory specimens testing positive for influenza in clinical laboratories increased (change of ≥ 0.5 percentage points) compared to the previous week. In all other regions the percentage remained stable compared to the previous week but is trending upwards. The regions with the highest percent positivity were regions 8 (13.2%), 4 (10.3%), 6 (7.7%), and 9 (7.2%). Influenza A(H1N1)pdm09 is the


predominant virus circulating in all regions, however a larger proportion (38%) of the viruses detected by public health labs have been influenza B in regions 4 and 6 compared to other regions (9-19%). For regional and state level data and age group distribution, please visit [FluView Interactive \(https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html\)](https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html). Viruses known to be associated with recent receipt of live attenuated influenza vaccine (LAIV) or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.

Clinical Laboratories

The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza virus) are used to monitor whether influenza activity is increasing or decreasing.

	Week 47	Data Cumulative since October 1, 2023 (Week 40)
No. of specimens tested	69,884	581,944
No. of positive specimens (%)	4,336 (6.2%)	17,814 (3.1%)
<i>Positive specimens by type</i>		
Influenza A	3,257 (75.1%)	12,873 (72.3%)
Influenza B	1,079 (24.9%)	4,941 (27.7%)

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, May 21, 2023 – November 25, 2023



<http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>

View Chart Data (/flu/weekly/weeklyarchives2023-2024/data/whoAllregt_cl47.html) | View Full Screen (</flu/weekly/WeeklyArchives2023-2024/WHONPHL47.html>)


Public Health Laboratories

The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating influenza viruses that belong to each influenza subtype/lineage.

	Week 47	Data Cumulative since October 1, 2023 (Week 40)
No. of specimens tested	1,798	22,823
No. of positive specimens	379	3,561

<i>Positive specimens by type/subtype</i>		
Influenza A	311 (82.1%)	2,845 (79.9%)
Subtyping Performed	202 (65.0%)	2,250 (79.1%)
(H1N1)pdm09	166 (82.2%)	1,969 (87.5%)
H3N2	36 (17.8%)	281 (12.5%)
H3N2v	0 (0.0%)	0 (0.0%)
Subtyping not performed	109 (35.0%)	595 (20.9%)
Influenza B	68 (17.9%)	716 (20.1%)
Lineage testing performed	47 (69.1%)	561 (78.4%)
Yamagata lineage	0 (0.0%)	0 (0.0%)
Victoria lineage	47 (100%)	561 (100%)
Lineage not performed	21 (30.9%)	155 (21.6%)

Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, National Summary, May 21, 2023 – November 25, 2023



<http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>

[View Chart Data \(/flu/weekly/weeklyarchives2023-2024/data/whoAllregt_phl47.html\)](/flu/weekly/weeklyarchives2023-2024/data/whoAllregt_phl47.html) | [View Full Screen \(/flu/weekly/weeklyarchives2023-2024/WhoPHL47.html\)](/flu/weekly/weeklyarchives2023-2024/WhoPHL47.html)

Additional virologic surveillance information for current and past seasons:

[Surveillance Methods \(/flu/weekly/overview.htm#LabSurveillance\)](/flu/weekly/overview.htm#LabSurveillance) | [FluView Interactive: National, Regional, and State Data \(http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html\)](#) or [Age Data \(https://gis.cdc.gov/grasp/fluview/flu_by_age_virus.html\)](https://gis.cdc.gov/grasp/fluview/flu_by_age_virus.html)

Influenza Virus Characterization

[\(/flu/weekly/overview.htm#VirusCharacterization\)](/flu/weekly/overview.htm#VirusCharacterization)

CDC performs [genetic \(https://www.cdc.gov/flu/about/professionals/genetic-characterization.htm\)](https://www.cdc.gov/flu/about/professionals/genetic-characterization.htm) and [antigenic \(https://www.cdc.gov/flu/about/professionals/antigenic.htm\)](https://www.cdc.gov/flu/about/professionals/antigenic.htm) characterization of viruses submitted by U.S. state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how

similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to influenza antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.

CDC has genetically characterized 818 influenza viruses collected since May 1, 2023.

Virus Subtype or Lineage	Genetic Characterization				
	Total No. of Subtype/Lineage Tested	HA Clade	Number (% of subtype/lineage tested)	HA Subclade	Number (% of subtype/lineage tested)
A/H1	441				
		6B.1A.5a	441 (100%)	2a	141 (32.0%)
				2a.1	300 (68.0%)
A/H3	81				
		3C.2a1b.2a	81 (100%)	2a.1b	1 (1.2%)
				2a.3a	4 (4.9%)
				2a.3a.1	75 (92.6%)
				2b	1 (1.2%)
B/Victoria	296				
		V1A	296 (100%)	3a.2	296 (100%)
B/Yamagata	0				
		Y3	0	Y3	0 (0%)

CDC antigenically characterizes (<https://www.cdc.gov/flu/about/professionals/antigenic.htm>) influenza viruses by hemagglutination inhibition (HI) (<http://www.cdc.gov/flu/professionals/laboratory/antigenic.htm>) (H1N1pdm09, H3N2, B/Victoria, and B/Yamagata viruses) or neutralization-based HINT (<https://www.cdc.gov/flu/spotlights/2018-2019/new-lab-method-test-flu.html>) (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2023-2024 Northern Hemisphere recommended cell or recombinant-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating

viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than or equal to 8-fold. Viruses selected for antigenic characterization are a subset representing the genetic changes in the surface proteins seen in genetically characterized viruses.

Influenza A Viruses

- **A(H1N1)pdm09:** One hundred and thirty-four A(H1N1)pdm09 viruses were antigenically characterized by HI, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Wisconsin/67/2022-like reference viruses representing the A(H1N1)pdm09 component for the cell- and recombinant-based influenza vaccines.
- **A(H3N2):** Twenty-three A(H3N2) viruses were antigenically characterized by HI or HINT, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer in HI or reacting at titers that were less than or equal to 8-fold of the homologous virus in HINT) by ferret antisera to cell-grown A/Darwin/6/2021-like reference viruses representing the A(H3N2) component for the cell- and recombinant-based influenza vaccines.

Influenza B Viruses

- **B/Victoria:** Eighty influenza B/Victoria-lineage virus were antigenically characterized by HI, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the cell- and recombinant-based influenza vaccines.
- **B/Yamagata:** No influenza B/Yamagata-lineage viruses were available for antigenic characterization.

Assessment of Virus Susceptibility to Antiviral Medications

CDC assesses susceptibility of influenza viruses to the antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir using next generation sequence analysis supplemented by laboratory assays. Information about antiviral susceptibility test methods can be found at [U.S. Influenza Surveillance: Purpose and \(https://www.cdc.gov/flu/weekly/overview.htm\) Methods | CDC \(https://www.cdc.gov/flu/weekly/overview.htm\)](https://www.cdc.gov/flu/weekly/overview.htm).

Viruses collected in the U.S. since October 01, 2023 were tested for antiviral susceptibility as follows:

Antiviral Medication			Total Viruses	A/H1	A/H3	B/Victoria
Neuraminidase Inhibitors	Oseltamivir	Viruses Tested	265	156	41	68
		Reduced Inhibition	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Highly Reduced Inhibition	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Peramivir	Viruses Tested	265	156	41	68
		Reduced Inhibition	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Highly Reduced Inhibition	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Zanamivir	Viruses Tested	265	156	41	68
		Reduced Inhibition	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Highly Reduced Inhibition	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PA Cap-Dependent Endonuclease Inhibitor	Baloxavir	Viruses Tested	262	153	41	68
		Decreased Susceptibility	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

High levels of resistance to the adamantanes (amantadine and rimantadine) persist among influenza A(H1N1)pdm09 and influenza A(H3N2) viruses (the adamantanes are not effective against influenza B viruses). Therefore, use of these antivirals for treatment and prevention of influenza A virus infection is not recommended and data from adamantane resistance testing are not presented.

Outpatient Respiratory Illness Surveillance

(<https://www.cdc.gov/flu/weekly/overview.htm#ILINet>)


The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with pathogens that can present with similar symptoms, including influenza viruses, SARS-CoV-2, and RSV. It is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a more complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is providing integrated information about COVID-19, influenza and RSV activity on a [website \(https://www.cdc.gov/respiratory-viruses/index.html\)](https://www.cdc.gov/respiratory-viruses/index.html) that is updated weekly. Information about other respiratory virus activity can be found on CDC's [National Respiratory and Enteric Virus Surveillance System \(NREVSS\) website \(https://www.cdc.gov/surveillance/nrevss/index.html\)](https://www.cdc.gov/surveillance/nrevss/index.html).

Outpatient Respiratory Illness Visits

Nationwide during Week 47, 3.9% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. This has increased compared to week 46 and is above the national baseline of 2.9% for the fourth consecutive week. ILI activity increased in 7 of the 10 HHS Regions (regions 1, 5, 6, 7, 8, 9, and 10) during week 47 compared to week 46 and, while stable compared to last week, is trending upward in Region 4. Percent of visits for ILI decreased in Region 3, but that may be attributed to low reporting during week 46. Eight regions are at or above their region-specific baselines (regions 1, 2, 4, 5, 6, 7, 8, and 9) this week. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

Season: 2023-24 and 5 previous seasons ▾

Percentage of Outpatient Visits for Respiratory Illness Reported by The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2023-24 Season and Selected Previous Seasons



- Check All
- 2023-24 National Baseline
- 2023-24 Season
- 2022-23 Season
- 2021-22 Season
- 2020-21 Season
- 2019-20 Season
- 2018-19 Season


View National and Regional Level Graphs and Data (<https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>) | [Download Chart Data](#) | [Download PowerPoint Presentation](#)

Outpatient Respiratory Illness Visits by Age Group

About 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

The percentage of visits for respiratory illness reported in ILINet has increased (change of > 0.1 percentage points) in two age groups (5-24 years and 50-64 years) in Week 47 compared to week 46 and is trending upward in all other age groups (0-4 years, 25-49 years, 65+ years).

Percentage of Outpatient Visits for Respiratory Illness by Age Group Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, May 21, 2023-November 25, 2023



(<http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html>)

[View Chart Data \(/flu/weekly/weeklyarchives2023-2024/data/iliage47.html\)](/flu/weekly/weeklyarchives2023-2024/data/iliage47.html) | [View Full Screen \(/flu/weekly/weeklyarchives2023-2024/ILIAge47.html\)](/flu/weekly/weeklyarchives2023-2024/ILIAge47.html)

Outpatient Respiratory Illness Activity Map

Data collected in ILINet are used to produce a measure of ILI activity* (</flu/weekly/overview.htm#ILINet>) by state/jurisdiction and Core Based Statistical Areas (CBSA).


Activity Level	Number of Jurisdictions		Number of CBSAs	
	Week 47 (Week ending Nov. 25, 2023)	Week 46 (Week ending Nov. 18, 2023)	Week 47 (Week ending Nov. 25, 2023)	Week 46 (Week ending Nov. 18, 2023)
Very High	2	2	10	12

High	11	10	56	59
Moderate	10	9	82	71
Low	11	9	156	128
Minimal	19	25	385	433
Insufficient Data	2	0	240	226


A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Outpatient Respiratory Illness Activity Map Determined by Data Reported to ILINet

This system monitors visits for respiratory illness that includes fever plus a cough or sore throat, also referred to as ILI, not laboratory confirmed influenza and may capture patient visits due to other respiratory pathogens that cause similar symptoms.



2023-24 Influenza Season Week 47 ending Nov 25, 2023



Season: 2023-24 ▾

Download Image Download Data

(<https://www.cdc.gov/flu/weekly/fluereport.xml>)View Full Screen (<http://gis.cdc.gov/grasp/fluview/main.html>)

*Data collected in ILINet may disproportionately represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

Additional information about medically attended visits for ILI for current and past seasons:
[Surveillance Methods \(flu/weekly/overview.htm#ILINet\)](#) | [FluView Interactive: National, Regional, and State Data \(http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html\)](#) or [ILI Activity Map \(https://gis.cdc.gov/grasp/fluview/main.html\)](#)

Hospitalization Surveillance

(<http://www.cdc.gov/flu/weekly/overview.htm#HospitalizationSurv>)


FluSurv-NET

The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.

A total of 1,131 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2023, and November 25, 2023; 923 (81.6%) were associated with influenza A virus, 162 (14.3%) with influenza B virus, 4 (0.4%) with influenza A virus and influenza B virus co-infection, and 42 (3.7%) with influenza virus for which the type was not determined. Among those with influenza A subtype information, 185 (83.3%) were A(H1N1)pdm09 and 36 (16.2%) were A(H3N2).

The weekly hospitalization rate observed in week 47 was 0.9 per 100,000 population. The overall cumulative hospitalization rate was 3.7 per 100,000 population. This cumulative hospitalization rate is the second highest cumulative in-season hospitalization rate observed in week 47, following the 2022-2023 season (16.6). Cumulative in-season hospitalization rates observed in week 46 from 2010-2011 through 2021-2022 ranged from 0.1 to 2.0.


When examining rates by age, the highest cumulative hospitalization rate per 100,000 population was among adults aged 65 years and older (8.9), followed by adults aged 50-64 years (4.9), and children aged 0-4 years (4.0). When examining unadjusted rates by race and ethnicity, the highest rate of hospitalization per 100,000 population was among non-Hispanic Black persons (6.4), followed by non-Hispanic American Indian or Alaska Native persons (4.4), Hispanic persons (3.7), non-Hispanic Asian persons (2.7), and non-Hispanic White persons (2.6).



<https://gis.cdc.gov/grasp/fluview/FluHospRates.html>

[View Full Screen \(/flu/weekly/weeklyarchives2023-2024/EIPRates47.html\)](/flu/weekly/weeklyarchives2023-2024/EIPRates47.html)

In this figure, cumulative rates for all seasons prior to the 2023-2024 season reflect end-of-season rates. For the 2023-2024 season, rates for recent hospital admissions are subject to reporting delays. As hospitalization data are reviewed each week, prior case counts and rates are updated accordingly.



<https://gis.cdc.gov/grasp/fluview/FluHospChars.html>

[View Full Screen \(/flu/weekly/weeklyarchives2023-2024/EIPConditions47.html\)](/flu/weekly/weeklyarchives2023-2024/EIPConditions47.html)

In this figure, weekly rates for all seasons prior to the 2023-24 season reflect end-of-season rates. For the 2023-24 season, rates for recent hospital admissions are subject to reporting delays and are shown as a dashed line for the current season. As hospitalization data are received each week, prior case counts and rates are updated accordingly.


Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

Surveillance Methods (<https://www.cdc.gov/flu/weekly/overview.htm#FluSurvNet>) | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity (<http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html>) or Data on Patient Characteristics

(<http://gis.cdc.gov/grasp/fluview/FluHospChars.html>) | RESP-NET Interactive (<https://www.cdc.gov/surveillance/resp-net/dashboard.html>)

National Healthcare Safety Network (NHSN) Hospitalization Surveillance

Hospitals report to NHSN the weekly number of patients admitted with laboratory-confirmed influenza. During Week 47, 4,268 patients with laboratory-confirmed influenza were admitted to a hospital. The number of patients admitted to a hospital with laboratory-confirmed influenza for Week 47 increased compared to Week 46 (change of >5%) nationally and in 9 of the 10 HHS Regions (1- 9). In Region 10, the number of hospitalizations slightly decreased compared to week 46.



</flu/weekly/weeklyarchives2023-2024/Protect47.html> View Chart Data </flu/weekly/weeklyarchives2023-2024/data/NHSNData47.csv> | [View Full Screen \(/flu/weekly/weeklyarchives2023-2024/Protect47.html\)](/flu/weekly/weeklyarchives2023-2024/Protect47.html)

Additional NHSN Hospitalization Surveillance information:

Surveillance Methods (<https://www.cdc.gov/flu/weekly/overview.htm#NHSN>) | Additional Data (<https://data.cdc.gov/Public-Health-Surveillance/Respiratory-Virus-Response-RVR-United-States-Hospi/9t9r-e5a3>) | FluView Interactive (<http://gis.cdc.gov/grasp/fluview/FluView12.html>)

Mortality Surveillance

<https://www.cdc.gov/flu/weekly/overview.htm#MortalitySurveillance>

National Center for Health Statistics (NCHS) Mortality Surveillance

Based on NCHS mortality surveillance data available on November 30, 2023, 0.1% of the deaths that occurred during the week ending November 25, 2023 (week 47), were due to influenza. This percentage remained stable (≤ 0.1 percentage point change) compared to Week 46, but is trending upwards slightly since early October. The data presented are preliminary and may change as more data are received and processed.


The percentages of deaths due to pneumonia and influenza (P&I) and due to pneumonia, influenza, or COVID-19 (PIC) will no longer be displayed in FluView but are available in [FluView Interactive](https://gis.cdc.gov/grasp/fluview/mortality.html) (<https://gis.cdc.gov/grasp/fluview/mortality.html>).

Season: 2023-24 Surveillance Area: National Age: All

Pneumonia and Influenza Mortality from the National Center for Health Statics Mortality Surveillance System

National Summary data through the week ending November 25, 2023

2019-24 Show Number of Influenza Deaths



[View Regional and State Level Data \(https://gis.cdc.gov/grasp/fluview/Mortality.html\)](https://gis.cdc.gov/grasp/fluview/Mortality.html) | [Download Chart Data](#) | [Download PowerPoint Presentation](#)

Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

Surveillance Methods (<https://www.cdc.gov/flu/weekly/overview.htm#NCHSMortality>) | [FluView Interactive](https://gis.cdc.gov/grasp/fluview/mortality.html)

Influenza-Associated Pediatric Mortality


Five influenza-associated pediatric deaths occurring during the 2023-2024 season were reported to CDC during week 47. The deaths occurred during weeks 43, 45, and 46 of 2023 (weeks ending October 28, November 11, and November 25, respectively). Two deaths were associated with influenza A(H1N1) viruses and three deaths were associated with influenza B viruses with no lineage determined.

A total of 8 influenza-associated pediatric deaths occurring during the 2023-2024 season have been reported to CDC.

Influenza-Associated Pediatric Deaths by Week of Death, 2020-21 season to 2023-24 season

Select up to 4 Seasons ▾ **Group By** Reported Virus Type

By Week Current Week Previous Weeks All Deaths



[View FluView Interactive](https://gis.cdc.gov/grasp/fluview/PedFluDeath.html) | [Download Chart Data](#) | [Download PowerPoint Presentation](#)

Additional pediatric mortality surveillance information for current and past seasons:

Surveillance Methods (<https://www.cdc.gov/flu/weekly/overview.htm#PediatricMortality>) | [FluView Interactive](https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html)

Trend Indicators

Increasing: ↑

Decreasing: ↓

Stable: →

Indicators Status by System

Clinical Labs: Up or down arrows indicate a change of greater than or equal to 0.5 percentage points in the percent of specimens positive for influenza compared to the previous week.

Outpatient Respiratory Illness (ILINet): Up or down arrows indicate a change of greater than 0.1 percentage points in the percent of visits due to respiratory illness (ILI) compared to the previous week.

NHSN Hospitalizations: Up or down arrows indicate change of greater than or equal to 5% of the number of patients admitted with laboratory-confirmed influenza compared to the previous week.

NCHS Mortality: Up or down arrows indicate change of greater than 0.1 percentage points of the percent of deaths due to influenza compared to the previous week.

Reference Footnotes

¹U.S. Influenza Surveillance: Purpose and Methods (2023 Oct). Centers for Disease Control and Prevention. <https://www.cdc.gov/flu/weekly/overview.htm#ILINet> (<https://www.cdc.gov/flu/weekly/overview.htm#ILINet>).

²Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season. MMWR Recomm Rep 2023;72(No. RR-2):1–25. DOI: <http://dx.doi.org/10.15585/mmwr.rr7202a1> <http://dx.doi.org/10.15585/mmwr.rr7202a1>

³Influenza Antiviral Medications: Summary for Clinicians (2023 Sept). Centers for Disease Control and Prevention. <https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm> (<https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm>).

Additional National and International Influenza Surveillance Information

FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These [FluView Interactive applications](http://www.cdc.gov/flu/weekly/fluviewinteractive.htm) (<http://www.cdc.gov/flu/weekly/fluviewinteractive.htm>) allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are [available from NIOSH](https://www.cdc.gov/niosh/topics/absences/default.html) (<https://www.cdc.gov/niosh/topics/absences/default.html>).

U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information.

Alabama (http://adph.org/influenza/)	Alaska (http://dhss.alaska.gov/dph/Epi/id/Pages/influenza/flu)
Colorado (https://www.mass.gov/info-details/influenza-reporting)	Connecticut (https://portal.ct.gov/DPH/EpidemiologEmerging-Infections/Influenza-Surveillance-and-Statist)
Georgia (https://dph.georgia.gov/flu-activity-georgia)	Hawaii (http://health.hawaii.gov/docd/resources/reports/influreports/)
Iowa (https://idph.iowa.gov/influenza/reports)	Kansas (http://www.kdheks.gov/flu/surveillance.htm)
Maryland (https://phpa.health.maryland.gov/influenza/fluwatch/)	Massachusetts (https://www.mass.gov/influenza)
Missouri (http://health.mo.gov/living/healthcondiseases/communicable/influenza/reports.php)	Montana (https://dphhs.mt.gov/publichealth/cdepi/diseases/inf)
New Jersey (http://www.nj.gov/health/cd/topics/flu.shtml)	New Mexico (https://nmhealth.org/about/erd/ideb/)
Ohio (http://www.flu.ohio.gov)	Oklahoma (https://oklahoma.gov/health/health-edudisease-service/disease-information/influenza-home-)
South Carolina (http://www.scdhec.gov/Health/DiseasesandConditions/InfectiousDiseases/Flu/FluData/)	South Dakota (https://doh.sd.gov/diseases/infectious/flu/surveillanc)
Vermont (http://www.healthvermont.gov/immunizations-infectious-disease/influenza/flu-activity-and-surveillance)	Virginia (http://www.vdh.virginia.gov/epidemiology/iin-virginia/influenza-surveillance/)
Wyoming (https://health.wyo.gov/publichealth/infectious-disease-epidemiology-unit/disease/influenza/)	New York City (http://www1.nyc.gov/site/doh/provi-topics/flu-alerts.page)

World Health Organization:

Additional influenza surveillance information from participating WHO member nations is available through FluNet [🔗](https://www.who.int/tools/flunet) (<https://www.who.int/tools/flunet>) and the Global Epidemiology Reports. [🔗](https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-surveillance-outputs) (<https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-surveillance-outputs>)

WHO Collaborating Centers for Influenza:

Australia [🔗](http://www.influenzacentre.org/Surveillance_Samples_Received.html) (http://www.influenzacentre.org/Surveillance_Samples_Received.html), China [🔗](http://www.chinaivdc.cn/cnic/) (<http://www.chinaivdc.cn/cnic/>), Japan [🔗](http://idsc.nih.go.jp/index.html) (<http://idsc.nih.go.jp/index.html>), the United Kingdom [🔗](https://www.crick.ac.uk/research/worldwide-influenza-centre) (<https://www.crick.ac.uk/research/worldwide-influenza-centre>), and the United States (<http://www.cdc.gov/flu/>) (CDC in Atlanta, Georgia)

Europe:

The most up-to-date influenza information from Europe is available from [WHO/Europe and the European Centre for Disease Prevention and Control](http://www.flunewseurope.org/) [ⓘ](http://www.flunewseurope.org/) (<http://www.flunewseurope.org/>).

Public Health Agency of Canada:

The most up-to-date influenza information from Canada is available in [Canada's weekly FluWatch report](http://www.phac-aspc.gc.ca/fluwatch/) [ⓘ](http://www.phac-aspc.gc.ca/fluwatch/) (<http://www.phac-aspc.gc.ca/fluwatch/>).

Public Health England:

The most up-to-date influenza information from the United Kingdom is available from [Public Health England](http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/) [ⓘ](http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/) (<http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/>).

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the [surveillance methods](http://www.cdc.gov/flu/weekly/overview.htm) (<http://www.cdc.gov/flu/weekly/overview.htm>) page.

Last Reviewed: December 1, 2023, 11:00 AM

Source: Centers for Disease Control and Prevention (<https://www.cdc.gov/>), National Center for Immunization and Respiratory Diseases (NCIRD) (<https://www.cdc.gov/ncird/index.html>)